Concurrently, THC intervention attenuated hepatic steatosis and fibrosis, mimicking the effects of the PPARG antagonist GW9662, which improves lipid metabolism in NASH mice (Xiao et al., 2023). Here, PPARG is linked to fatty liver disease.